BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 23780645)

  • 1. The association of pre-treatment neutrophil to lymphocyte ratio with overall survival in patients with glioblastoma multiforme.
    Bambury RM; Teo MY; Power DG; Yusuf A; Murray S; Battley JE; Drake C; O'Dea P; Bermingham N; Keohane C; Grossman SA; Moylan EJ; O'Reilly S
    J Neurooncol; 2013 Aug; 114(1):149-54. PubMed ID: 23780645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutrophil-lymphocyte ratio dynamics during concurrent chemo-radiotherapy for glioblastoma is an independent predictor for overall survival.
    Mason M; Maurice C; McNamara MG; Tieu MT; Lwin Z; Millar BA; Menard C; Laperriere N; Milosevic M; Atenafu EG; Mason W; Chung C
    J Neurooncol; 2017 May; 132(3):463-471. PubMed ID: 28332000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of neutrophil to lymphocyte ratio and prognostic nutritional index with other clinical and molecular biomarkers for prediction of glioblastoma multiforme outcome.
    Garrett C; Becker TM; Lynch D; Po J; Xuan W; Scott KF; de Souza P
    PLoS One; 2021; 16(6):e0252614. PubMed ID: 34138894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme.
    Lopes M; Carvalho B; Vaz R; Linhares P
    J Neurooncol; 2018 Jan; 136(1):173-180. PubMed ID: 29076002
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Cumulative Score Based on Preoperative Neutrophil-Lymphocyte Ratio and Fibrinogen in Predicting Overall Survival of Patients with Glioblastoma Multiforme.
    Hao Y; Li X; Chen H; Huo H; Liu Z; Tian F; Chai E
    World Neurosurg; 2019 Aug; 128():e427-e433. PubMed ID: 31042598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Value of the Pretreatment Neutrophil/Lymphocyte Ratio in Patients with Glioblastoma Multiforme Brain Tumors: A Retrospective Cohort Study of Patients Treated with Combined Modality Surgery, Radiation Therapy, and Temozolomide Chemotherapy.
    Brenner A; Friger M; Geffen DB; Kaisman-Elbaz T; Lavrenkov K
    Oncology; 2019; 97(5):255-263. PubMed ID: 31288238
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factors impacting survival following second surgery in patients with glioblastoma in the temozolomide treatment era, incorporating neutrophil/lymphocyte ratio and time to first progression.
    McNamara MG; Lwin Z; Jiang H; Templeton AJ; Zadeh G; Bernstein M; Chung C; Millar BA; Laperriere N; Mason WP
    J Neurooncol; 2014 Mar; 117(1):147-52. PubMed ID: 24469854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma.
    Han S; Liu Y; Li Q; Li Z; Hou H; Wu A
    BMC Cancer; 2015 Sep; 15():617. PubMed ID: 26341881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic Significance of Indicators of Systemic Inflammatory Responses in Glioblastoma Patients.
    Kaya V; Yıldırım M; Yazıcı G; Yalçın AY; Orhan N; Güzel A
    Asian Pac J Cancer Prev; 2017 Dec; 18(12):3287-3291. PubMed ID: 29286221
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of pre-treatment neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in patients with glioblastoma.
    Yersal Ö; Odabaşi E; Özdemir Ö; Kemal Y
    Mol Clin Oncol; 2018 Oct; 9(4):453-458. PubMed ID: 30233797
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.
    Sun J; Ning H; Sun J; Qu X
    Urol Oncol; 2016 May; 34(5):239.e9-15. PubMed ID: 26803433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated preoperative neutrophil-to-lymphocyte ratio as a predictor of worse survival after resection in patients with brain metastasis.
    Mitsuya K; Nakasu Y; Kurakane T; Hayashi N; Harada H; Nozaki K
    J Neurosurg; 2017 Aug; 127(2):433-437. PubMed ID: 27911233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of the combination of neutrophil-to-lymphocyte ratio and Glasgow prognostic score in colorectal cancer: a retrospective cohort study.
    Inamoto S; Kawada K; Okamura R; Hida K; Sakai Y
    Int J Colorectal Dis; 2019 Jul; 34(7):1303-1315. PubMed ID: 31177316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil/Lymphocyte Ratio Is an Independent Prognostic Factor in Elderly Patients with High-Grade Gliomas.
    Gan Y; Zhou X; Niu X; Li J; Wang T; Zhang H; Yang Y; Liu Y; Mao Q
    World Neurosurg; 2019 Jul; 127():e261-e267. PubMed ID: 30898756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil to lymphocyte ratio (NLR) as an indicator of poor prognosis in stage IV non-small cell lung cancer.
    Cedrés S; Torrejon D; Martínez A; Martinez P; Navarro A; Zamora E; Mulet-Margalef N; Felip E
    Clin Transl Oncol; 2012 Nov; 14(11):864-9. PubMed ID: 22855161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Indicators of Systemic Inflammatory Response on Survival in Glioblastoma Multiforme.
    Mermut O; Inanc B
    Turk Neurosurg; 2020; 30(5):658-665. PubMed ID: 32530473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the prognostic role of neutrophil-to-lymphocyte ratio following complete resection of thymoma.
    Muriana P; Carretta A; Ciriaco P; Bandiera A; Negri G
    J Cardiothorac Surg; 2018 Nov; 13(1):119. PubMed ID: 30454002
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Validation of the neutrophil-to-lymphocyte ratio as a prognostic factor in a cohort of European prostate cancer patients.
    Langsenlehner T; Thurner EM; Krenn-Pilko S; Langsenlehner U; Stojakovic T; Gerger A; Pichler M
    World J Urol; 2015 Nov; 33(11):1661-7. PubMed ID: 25617235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.
    Grenader T; Waddell T; Peckitt C; Oates J; Starling N; Cunningham D; Bridgewater J
    Ann Oncol; 2016 Apr; 27(4):687-92. PubMed ID: 26787231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.